Hepatoprotective and antioxidant activities of extracts from Salvia–Nelumbinis naturalis against nonalcoholic steatohepatitis induced by methionine- and choline-deficient diet in mice

Journal of Translational Medicine

Guang Ji²  Dongfei Li¹  Ying Li³  Li Zhang²  Xiangbing Shu²  Hanchen Xu²  Lei Wang³  Haiyan Song²  Yang Liu² 

[1] Department of Traditional Chinese Medicine, East Hospital, Tongji University, Shanghai 200120, China;Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China;Department of Liver Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China

关键词: Oxidative stress;    Liver injury;    NASH;    Salvia¿Nelumbinis naturalis;   

Others  :  1147212
DOI  :  10.1186/s12967-014-0315-x

 received in 2014-08-13, accepted in 2014-10-28,  发布年份 2014

【 摘 要 】

Background

Nonalcoholic steatohepatitis (NASH), the advanced stage of nonalcoholic fatty liver disease that is characterized by both steatosis and severe injury in liver, still lacks efficient treatment. The traditional Chinese formula Salvia¿Nelumbinis naturalis (SNN) is effectively applied to improve the symptoms of nonalcoholic simple fatty liver (NAFL) patients. Previous studies have confirmed that SNN could reduce the liver lipid deposition and serum transaminases of NAFL experimental models. This study aims to determine whether SNN is effective for murine NASH model and investigate the underlying pharmacological mechanisms.

Methods

C57BL/6 J mice were fed with methionine- and choline-deficient (MCD) diet for six weeks to induce NASH. Simultaneously, SNN or saline was intragastrically administered daily to the mice in the SNN or model group, respectively. A standard diet was given to the control mice. Serum biochemical indices and tumor necrosis factor-? were measured. Liver histopathology was observed, and the contents of triglycerides and lipid peroxide malondialdehyde (MDA) in liver homogenates were evaluated. The hepatic expression and/or activation of genes associated with inflammation, apoptosis, and oxidative stress were determined by quantitative RT-PCR or Western blot analysis.

Results

The prominent liver steatosis displayed in the NASH model was prevented by SNN. The liver injury of NASH mice was obviously manifested by the increased levels of serum transaminases and bilirubin, as well as the lobular inflammation, elevated pro-inflammatory cytokines, and upregulated apoptosis in liver tissues. SNN administration improved the aforementioned pathological changes. The increased hepatic levels of MDA and cytochrome P450 2E1 of the model confirmed the unregulated balance of oxidative stress. The hepatic expression of nuclear factor erythroid 2-related factor 2 and its target genes decreased, whereas c-Jun N-terminal kinase activation in the model mice increased. Treating the mice with SNN significantly improved oxidative stress-related harmful factors.

Conclusions

This study shows that SNN can protect the liver from severe steatosis and damage induced by MCD diet, which suggests the potential use of SNN on the treatment of NASH patient. The results also indicate that improving the hepatic antioxidant capability of the liver may contribute to the underlying hepatoprotective mechanism.

【 授权许可】

   
2014 Liu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G: A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010, 53:372-384.
• [2]Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA: Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140:124-131.
• [3]Cohen JC, Horton JD, Hobbs HH: Human fatty liver disease: old questions and new insights. Science 2011, 332:1519-1523.
• [4]Petta S, Muratore C, Craxi A: Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 2009, 41:615-625.
• [5]Oliveira CP, da Costa Gayotto LC, Tatai C, Della Bina BI, Janiszewski M, Lima ES, Abdalla DS, Lopasso FP, Laurindo FR, Laudanna AA: Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline-deficient diet. J Cell Mol Med 2002, 6:399-406.
• [6]Aubert J, Begriche K, Knockaert L, Robin MA, Fromenty B: Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. Clin Res Hepatol Gastroenterol 2011, 35:630-637.
• [7]James O, Day C: Non-alcoholic steatohepatitis: another disease of affluence. Lancet 1999, 353:1634-1636.
• [8]Robertson G, Leclercq I, Farrell GC: Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 2001, 281:G1135-G1139.
• [9]Niemela O, Parkkila S, Juvonen RO, Viitala K, Gelboin HV, Pasanen M: Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases. J Hepatol 2000, 33:893-901.
• [10]He J, Hu B, Shi X, Weidert ER, Lu P, Xu M, Huang M, Kelley EE, Xie W: Activation of the aryl hydrocarbon receptor sensitizes mice to nonalcoholic steatohepatitis by deactivating mitochondrial sirtuin deacetylase Sirt3. Mol Cell Biol 2013, 33:2047-2055.
• [11]Wanless IR, Shiota K: The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis 2004, 24:99-106.
• [12]Harrison SA, Kadakia S, Lang KA, Schenker S: Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol 2002, 97:2714-2724.
• [13]Cortez-Pinto H, de Moura MC, Day CP: Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol 2006, 44:197-208.
• [14]Dinarello CA: The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 2002, 20:S1-S13.
• [15]Pober JS: Endothelial activation: intracellular signaling pathways. Arthritis Res 2002, 4(Suppl 3):S109-S116. BioMed Central Full Text
• [16]Alisi A, Manco M, Devito R, Piemonte F, Nobili V: Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2010, 50:645-649.
• [17]Han YP, Tuan TL, Hughes M, Wu H, Garner WL: Transforming growth factor-beta - and tumor necrosis factor-alpha -mediated induction and proteolytic activation of MMP-9 in human skin. J Biol Chem 2001, 276:22341-22350.
• [18]Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L: Molecular mechanisms involved in NAFLD progression. J Mol Med 2009, 87:679-695.
• [19]Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, Oshima M, Fujii C, Mukaida N: Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008, 118:560-570.
• [20]Marcolin E, San-Miguel B, Vallejo D, Tieppo J, Marroni N, Gonzalez-Gallego J, Tunon MJ: Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis. J Nutr 2012, 142:1821-1828.
• [21]Song HY, Zhang L, Pan JL, Yang LL, Ji G: Bioactivity of five components of Chinese herbal formula Jiangzhi granules against hepatocellular steatosis. J Integr Med 2013, 11:262-268.
• [22]Ma ZS, Liu T, Zheng PY, Xing LJ, Ji G: Effect of Chinese Medicine Jiangzhi Granula on Hepaticlipid of Nonalcoholic Fatty Liver Disease Rats. Chin Arch Tradit Chin Med 2007, 25:942-944.
• [23]Pan J, Wang M, Song H, Wang L, Ji G: The efficacy and safety of traditional chinese medicine (jiang zhi granule) for nonalcoholic Fatty liver: a multicenter, randomized, placebo-controlled study. Evidence-based Complement Altern Med: eCAM 2013, 2013:965723.
• [24]Zhang L, Liu T, Wang M, Xing LJ, Ji G, Zheng PY: Effect of Jiang zhi granula on leptin and leptin receptor of hypothalamus in rats with nonalcoholic liver disease. Chin J Integr Tradit West Med Liver Dis 2009, 19:88-91.
• [25]Zheng PY, Zhang L, Liu T, Wang M, Xing LJ, Ji G: Effect of Jiangzhi granule on STAT3 expression in hypothalamus of rats with nonalcoholic fatty liver disease. World Chin J Digestol 2009, 17:753-757.
• [26]Wang M, Sun S, Wu T, Zhang L, Song H, Hao W, Zheng P, Xing L, Ji G: Inhibition of LXRalpha/SREBP-1c-Mediated Hepatic Steatosis by Jiang-Zhi Granule. Evidence-based Complement Altern Med: eCAM 2013, 2013:584634.
• [27]Zhang L, Xu J, Song H, Yao Z, Ji G: Extracts from Salvia-Nelumbinis naturalis alleviate hepatosteatosis via improving hepatic insulin sensitivity. J Transl Med 2014, 12:236. BioMed Central Full Text
• [28]Lu YL, Wang M, Zhang L, He YQ, Yang L, Wang CH, Wang ZT, Ji G: Simultaneous determination of six components in the `Jiang-Zhi¿ granule by UPLC-MS analysis. Chin J Nat Med 2010, 8:449-455.
• [29]Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR: CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000, 105:1067-1075.
• [30]National Research Council (U.S.). Committee for the Update of the Guide for the Care and Use of Laboratory Animals., Institute for Laboratory Animal Research (U.S.), National Academies Press (U.S.): Guide for the care and use of laboratory animals. 8th edn. Washington, D.C.: National Academies Press; 2011.
• [31]Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA, Network NCR: Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011, 53:810-820.
• [32]Wang Y, Ausman LM, Russell RM, Greenberg AS, Wang XD: Increased apoptosis in high-fat diet-induced nonalcoholic steatohepatitis in rats is associated with c-Jun NH2-terminal kinase activation and elevated proapoptotic Bax. J Nutr 2008, 138:1866-1871.
• [33]Marcolin E, Forgiarini LF, Tieppo J, Dias AS, Freitas LA, Marroni NP: Methionine- and choline-deficient diet induces hepatic changes characteristic of non-alcoholic steatohepatitis. Arq Gastroenterol 2011, 48:72-79.
• [34]Phung N, Pera N, Farrell G, Leclercq I, Hou JY, George J: Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis. Int J Mol Med 2009, 24:171-180.
• [35]George J, Pera N, Phung N, Leclercq I, Yun Hou J, Farrell G: Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol 2003, 39:756-764.
• [36]Fan JG, Qiao L: Commonly used animal models of non-alcoholic steatohepatitis. Hepatobiliary Pancreat Dis Int 2009, 8:233-240.
• [37]Schattenberg JM, Galle PR: Animal models of non-alcoholic steatohepatitis: of mice and man. Dig Dis 2010, 28:247-254.
• [38]London RM, George J: Pathogenesis of NASH: animal models.Clinics in liver disease 2007, 11:55¿74, viii.
• [39]Min AK, Kim MK, Kim HS, Seo HY, Lee KU, Kim JG, Park KG, Lee IK: Alpha-lipoic acid attenuates methionine choline deficient diet-induced steatohepatitis in C57BL/6 mice. Life Sci 2012, 90:200-205.
• [40]Park HJ, Han JM, Kim HG, Choi MK, Lee JS, Lee HW, Son CG: Chunggan extract (CGX), methionine-and choline-deficient (MCD) diet-induced hepatosteatosis and oxidative stress in C57BL/6 mice. Hum Exp Toxicol 2013, 32:1258-1269.
• [41]Sies H: Oxidative stress: from basic research to clinical application. Am J Med 1991, 91:31S-38S.
• [42]Koruk M, Taysi S, Savas MC, Yilmaz O, Akcay F, Karakok M: Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. Ann Clin Lab Sci 2004, 34:57-62.
• [43]Koek GH, Liedorp PR, Bast A: The role of oxidative stress in non-alcoholic steatohepatitis.Clin Chim Acta 2011, 412:1297¿1305.
• [44]Chalasani N, Deeg MA, Crabb DW: Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004, 99:1497-1502.
• [45]Loguercio C, De Girolamo V, de Sio I, Tuccillo C, Ascione A, Baldi F, Budillon G, Cimino L, Di Carlo A, Di Marino MP, Morisco F, Picciotto F, Terracciano L, Vecchione R, Verde V, Del Vecchio Blanco C: Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J Hepatol 2001, 35:568-574.
• [46]Lieber CS: CYP2E1: from ASH to NASH. Hepatology research: the official journal of the Japan Society of Hepatology 2004, 28:1-11.
• [47]Abdelmegeed MA, Banerjee A, Yoo SH, Jang S, Gonzalez FJ, Song BJ: Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis. J Hepatol 2012, 57:860-866.
• [48]Gong P, Cederbaum AI: Nrf2 is increased by CYP2E1 in rodent liver and HepG2 cells and protects against oxidative stress caused by CYP2E1. Hepatology 2006, 43:144-153.
• [49]Zhang YK, Yeager RL, Tanaka Y, Klaassen CD: Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine- and choline-deficient diet. Toxicol Appl Pharmacol 2010, 245:326-334.
• [50]Chowdhry S, Nazmy MH, Meakin PJ, Dinkova-Kostova AT, Walsh SV, Tsujita T, Dillon JF, Ashford ML, Hayes JD: Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic Biol Med 2010, 48:357-371.
• [51]Orsu P, Murthy BV, Akula A: Cerebroprotective potential of resveratrol through anti-oxidant and anti-inflammatory mechanisms in rats. J Neural Transm 2013, 120:1217-1223.
• [52]Moghaddam HK, Baluchnejadmojarad T, Roghani M, Khaksari M, Norouzi P, Ahooie M, Mahboobi F: Berberine ameliorate oxidative stress and astrogliosis in the hippocampus of STZ-induced diabetic rats. Mol Neurobiol 2014, 49:820-826.
• [53]Domitrovic R, Jakovac H, Marchesi VV, Blazekovic B: Resolution of liver fibrosis by isoquinoline alkaloid berberine in CCl(4)-intoxicated mice is mediated by suppression of oxidative stress and upregulation of MMP-2 expression. J Med Food 2013, 16:518-528.
• [54]Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ: Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125:437-443.
• [55]Schattenberg JM, Singh R, Wang Y, Lefkowitch JH, Rigoli RM, Scherer PE, Czaja MJ: JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 2006, 43:163-172.
• [56]Yamamoto K, Ichijo H, Korsmeyer SJ: BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 1999, 19:8469-8478.
• [57]Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ: Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001, 292:727-730.
• [58]Miranda-Mendez A, Lugo-Baruqui A, Armendariz-Borunda J: Molecular basis and current treatment for alcoholic liver disease. Int J Environ Res Public Health 2010, 7:1872-1888.
• [59]Day CP: Treatment of alcoholic liver disease. Liver Transpl 2007, 13:S69-S75.